For the subset of these diseases in which eosinophilia is seen, our data suggest that targeting eosinophils could have therapeutic efficacy while avoiding potential toxicities such as impaired host defenses to infections that could occur following global inhibition of the IL-23/IL-17 axis [46]. The gene discussed is IL23A; the disease is infection.